McKesson Corporation (MCK)
| Market Cap | 101.04B +6.8% |
| Revenue (ttm) | 410.98B +8.8% |
| Net Income | 4.59B +45.1% |
| EPS | 37.48 +50.2% |
| Shares Out | 116.59M |
| PE Ratio | 23.12 |
| Forward PE | 18.62 |
| Dividend | $3.76 (0.43%) |
| Ex-Dividend Date | Sep 1, 2026 |
| Volume | 452,045 |
| Open | 865.00 |
| Previous Close | 869.36 |
| Day's Range | 858.76 - 871.00 |
| 52-Week Range | 715.31 - 999.00 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 979.36 (+13.01%) |
| Earnings Date | Nov 4, 2026 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for MCK stock is "Buy." The 12-month stock price target is $979.36, which is an increase of 13.01% from the latest price.
News
McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026. The company will host ...
McKesson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Double-digit growth was achieved in key segments, with raised EPS and AOI guidance reflecting strong momentum. The PMG acquisition enhances oncology and biopharma capabilities, while capital deployment remains focused on growth and shareholder returns. Continued expansion in specialty platforms and confidence in navigating policy changes were emphasized.
McKesson Transcript: Wells Fargo 21st Annual Healthcare Conference
Strategic focus remains on oncology, biopharma, and supply chain, highlighted by the $2.25B Precision Medicine Group acquisition, robust Q1 growth in key segments, and disciplined capital allocation. AI and technology investments, stable generics, and biosimilar opportunities support a positive outlook.
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an America...
McKesson announces cybersecurity incident, investigation in early stages
In a regulatory filing, the company stated, “On August 25, 2026, McKesson (MCK) Corporation discovered a cybersecurity incident affecting its information systems. An investigation of the incident is i...
Morgan Stanley views Precision Medicine as logical addition to McKesson platform
Commenting on McKesson’s (MCK) acquisition of Precision Medicine Group for $2.25B, Morgan Stanley says the company’s CRO acquisition was a long time coming. Precision Medicine Group advances McKesson’...
McKesson signs agreement to acquire Precision Medicine Group
McKesson (MCK) announced that it signed a definitive agreement to acquire Precision Medicine Group, a global provider of clinical research and biopharma commercialization services. McKesson will acqui...
McKesson to buy Precision Medicine Group in about $2.25 billion deal
U.S. drug distributor McKesson said on Tuesday it would buy clinical research and biopharma commercialization services provider Precision Medicine Group in a deal valued at about $2.25 billion.
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global p...
McKesson price target raised to $1,000 from $925 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on McKesson (MCK) to $1,000 from $925 and keeps an Overweight rating on the shares. The firm updated the company’s model…
McKesson initiated with a Sector Perform at RBC Capital
RBC Capital analyst Ryan Halsted initiated coverage of McKesson (MCK) with a Sector Perform rating and $845 price target The firm believes the company’s integrated model and specialty drug exposure…
McKesson price target raised to $933 from $812 at Wells Fargo
Wells Fargo raised the firm’s price target on McKesson (MCK) to $933 from $812 and keeps an Equal Weight rating on the shares. The firm is increasing estimates following constructive…
McKesson price target raised to $977 from $966 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on McKesson (MCK) to $977 from $966 and keeps an Overweight rating on the shares.
McKesson price target raised to $1,015 from $955 at Baird
Baird raised the firm’s price target on McKesson (MCK) to $1,015 from $955 and keeps an Outperform rating on the shares. The firm updated its model following quarterly results which…
McKesson price target raised to $1,000 from $860 at Evercore ISI
Evercore ISI raised the firm’s price target on McKesson (MCK) to $1,000 from $860 and keeps an Outperform rating on the shares.
McKesson price target raised to $1,006 from $989 at TD Cowen
TD Cowen raised the firm’s price target on McKesson (MCK) to $1,006 from $989 and keeps a Buy rating on the shares. The firm updated its model following a strong…
McKesson price target raised to $1,080 from $1,050 at UBS
UBS raised the firm’s price target on McKesson (MCK) to $1,080 from $1,050 and keeps a Buy rating on the shares.
McKesson price target raised to $905 from $885 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on McKesson (MCK) to $905 from $885 and keeps a Neutral rating on the shares.
McKesson raises annual profit forecast on strong growth in specialty drug business
Drug distributor McKesson on Wednesday raised its annual profit forecast after beating first-quarter earnings estimates, on strength in its oncology and specialty drug businesses.
McKesson Earnings Call Transcript: Q1 2027
Revenue grew 8% to $105.4B and adjusted EPS rose 20% to $9.93, with three segments posting double-digit profit growth. Full-year EPS guidance was raised, supported by strong specialty and GLP-1 demand, robust cash flow, and continued capital returns.
McKesson Earnings release: Q1 2027
McKesson released its Q1 2027 earnings on August 5, 2026, summarizing the period's financial results.
McKesson Slides: Q1 2027
McKesson has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
McKesson Quarterly report: Q1 2027
McKesson has published its Q1 2027 quarterly earnings report on August 5, 2026.
McKesson reports Q1 adjusted EPS $9.93, consensus $9.54
Reports Q1 revenue $105.4B, consensus $103.74B. “McKesson (MCK) delivered a strong start to fiscal 2027, underscored by momentum across the enterprise and disciplined execution against our strategic p...